[On the treatment of arteriosclerotic retinopathy with Cosaldon A+E (author's transl)].
Cosaldon A+E was applied in 61 patients, most of whom presented severe vascular degenerative retinochoroidal circulatory disorders and chronic glaucoma. The treatment, mostly consisting of 3--2 x 1 tablet per day, was well tolerated and resulted in marked (43 patients) and moderate (8 patients) improvement of visual function. In ten patients the symptoms remained unchanged. Particularly the improvement found in 4 patients presenting chronic glaucoma "without pressure" are worth mentioning. Besides, the symptomatology of chronic cerebrovascular insufficiency presented by most of the patients was positively influenced. Cosaldon A+E above all renders more promising the treatment of vascular processes in the eye-ground, such as the chorioretinopathy, which, in view of the unfavourable prognosis of the disease, is deemed a remarkable progress. Likewise the product seems to exert a beneficial effect in patients with chronic glaucoma.
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000150:complications*; D002825:Chorioretinitis / Q000188:drug therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use; D013805:Theobromine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D004338:Drug Combinations; D009539:Nicotinic Acids; D014665:Vasodilator Agents; D013805:Theobromine
Zur Behandlung der arteriosklerotischen Chorioretinopathie mit Cosaldon A+E.